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Background: Renin-angiotensin system (RAS) breakthrough may occur in heart failure despite optimum ACE-inhibition (ACE-I). We examined the 
effect of adding the direct renin inhibitor aliskiren 150mg/d in patients in the ALOFT trial.
Methods: Those receiving an evidence-based daily-dose of ACE-I e.g. >150 mg captopril, >20 mg enalapril, >10 mg ramipril etc were compared 
with those <target-dose. Outcome: change in plasma B-type natriuretic peptide (BNP)concentration from baseline to 3 months.
Results: Compared with placebo, aliskiren reduced BNP by 33% in the >target-dose ACE-I group and by 31% in the <target-dose group (interaction 
p=0.94) [Table].
Conclusions: Additional RAS inhibition with aliskiren reduced BNP, even in patients receiving optimum ACE-I.
<Target ACE-I dose >/=Target ACE-I dose
Placebo (n=56) Aliskiren (n=53) Placebo (n=33) Aliskiren (n=48)
Baseline BNP, pg/mL, 
median (range)
219 (13,1169) 237 (13,1189) 185 (41,1285) 204 (13,1711)
Change in BNP from 
baseline to 3 mo., pg/mL, 
median (range)
-6.0 (-850,267) -35 (-457, 1576) -4.0 (-245,971) -63.0 (-1128,248)
Ratio geometric mean 
BNP at 3 mo. vs. baseline 
(95% CI)
0.99 (0.68,1.44) 0.68 (0.47,0.99) 0.81 (0.54,1.22) 0.54 (0.38,0.78)
Ratio aliskiren/placebo 
(95% CI)
0.69 (0.47,1.02) 0.67 (0.44,1.03)
